NeoGenomics, Inc. is a pharmaceutical company based in the United States that specializes in genetic testing services for cancer patients. With a low ESG risk rating score of 20.0, the company operates two segments - Clinical Services and Advanced Diagnostics. Their services include Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, and more. NeoGenomics also supports pharmaceutical companies in drug development programs. Major revenue is generated through Clinical Services.